sever
acut
respiratori
syndrom
outbreak
order
track
similarli
highli
contagi
sever
lower
respiratori
ill
pneumonia
symptom
chines
govern
paid
great
attent
unexplain
pneumonia
phrase
coin
chines
human
unexplain
pneumonia
surveil
network
chupsn
publish
refer
pneumonia
could
character
rapid
progress
normal
white
blood
cell
count
rang
poor
respons
although
common
pathogen
caus
virus
atyp
pathogen
overlap
clinic
manifest
imped
abil
clinician
directli
diagnos
caus
pathogen
may
lead
unnecessari
antimicrobi
usag
thu
rapid
precis
diagnosi
caus
agent
critic
prompt
manag
date
tradit
method
use
help
clinic
approach
diagnos
howev
method
certain
disadvantag
exampl
rapid
antigen
test
sensit
adult
influenza
depend
use
specif
scientif
techniqu
wherea
cultur
virus
take
recent
year
increas
use
nucleic
acid
amplif
test
naat
method
detect
viral
pathogen
due
excel
diagnost
abil
identifi
broad
spectrum
filmarray
multiplex
pcr
biofir
diagnost
inc
compani
naat
method
use
detect
multipl
pathogen
singl
test
may
filmarray
respiratori
panel
fda
clear
detect
respiratori
viral
pathogen
includ
influenza
subtyp
b
respiratori
syncyti
viru
rsv
human
metapneumoviru
adenoviru
coronaviru
human
rhinovirusenteroviru
parainfluenza
includ
subtyp
three
bacteria
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
turnaround
time
use
panel
approxim
hour
thu
techniqu
eas
rapid
accur
identif
pathogen
caus
increas
implement
clinic
microbiolog
laboratori
studi
requir
determin
clinic
diagnost
abil
method
influenc
patient
outcom
antimicrobi
usag
accordingli
studi
aim
evalu
clinic
impact
patient
treatment
compar
convent
method
end
prospect
enrol
patient
diagnos
analyz
pathogen
detect
abil
moreov
evalu
clinic
impact
patient
base
comparison
clinic
outcom
medic
record
patient
cohort
enrol
period
octob
march
data
cohort
retrospect
collect
period
octob
march
aim
evalu
effect
use
filmarray
term
quantif
antimicrobi
use
use
antivir
drug
adjust
antibiot
treatment
prospect
cohort
enrol
shanghai
china
octob
march
includ
two
consecut
winter
season
elig
patient
recruit
base
modifi
definit
chupsn
follow
fever
b
pneumonia
radiograph
result
c
normal
slightli
decreas
number
total
white
blood
cell
earli
stage
diseas
durat
ill
day
e
poor
respons
initi
antibiot
treatment
f
minimum
age
year
old
sampl
enrol
patient
submit
analys
accordingli
refer
group
record
demograph
characterist
patient
relev
clinic
data
patient
group
lost
complet
data
refer
intervent
group
histor
control
cohort
retrospect
recruit
use
inclus
criteria
among
patient
hospit
octob
march
time
avail
similar
group
relev
data
patient
within
control
cohort
record
within
hour
patient
admiss
respiratori
tract
specimen
collect
includ
bronchoalveolar
lavag
fluid
balf
among
patient
gave
consent
undergo
bronchoscopi
sputum
expector
evid
nasopharyng
swab
np
bronchoscopi
perform
expector
sampl
collect
notabl
lower
respiratori
tract
specimen
given
higher
prioriti
balf
sputum
np
studi
soon
possibl
sampl
specimen
transfer
laboratori
infecti
diseas
research
institut
huashan
hospit
shanghai
profession
pulmonari
physician
oversaw
balf
sampl
collect
np
sputum
perform
clinic
physician
per
clinic
standard
oper
procedur
notabl
sampl
np
balf
viscos
low
requir
sampl
prepar
filmarray
panel
test
wherea
viscou
sampl
sputum
use
previous
describ
dunk
swirl
remain
specimen
store
freezer
use
studi
use
version
autom
multiplex
pcr
detect
platform
design
detect
common
pathogen
caus
respiratori
infect
singl
specimen
turnaround
time
hour
test
use
panel
perform
follow
manufactur
instruct
specimen
report
influenza
subtyp
perform
analysi
influenza
subtyp
nucleic
acid
extract
kit
qiaamp
viral
rna
mini
kit
qiagen
pcr
kit
influenza
ab
influenza
avian
influenza
avian
influenza
viral
rna
detect
kit
fluoresc
pcr
use
accord
respect
manufactur
instruct
detect
viral
rna
nucleic
acid
extract
aliquot
clinic
specimen
use
qiaamp
viral
rna
mini
kit
individu
pcr
assay
perform
volum
pcr
system
appli
biosystem
use
isol
nucleic
acid
univers
master
mix
rna
master
mix
zhijiang
biolog
univers
amplif
condit
consist
one
cycl
minut
one
cycl
minut
follow
cycl
second
second
taqman
fluorogen
chemistri
detect
set
primer
probe
control
includ
reaction
plate
specimen
reach
threshold
cycl
consid
posit
patient
group
tradit
laboratori
diagnost
test
respiratori
infect
perform
accord
request
physician
includ
smear
cultur
serolog
test
serolog
test
studi
pneumoslid
igm
vircel
commerci
kit
base
indirect
immunofluoresc
studi
clinic
data
includ
antimicrobi
use
adjust
antimicrobi
therapi
compar
group
retrospect
control
group
turnaround
time
defin
length
time
sampl
collect
receiv
result
antimicrobi
use
quantifi
defin
daili
dose
ddd
number
calcul
drug
total
dosag
g
drug
ddd
index
adjust
antimicrobi
therapi
defin
chang
antimicrobi
regimen
immedi
receiv
result
u
test
use
comparison
quantit
data
spss
ibm
use
data
analys
use
graphpad
draw
graph
ethic
committe
huashan
hospit
shanghai
approv
studi
juli
particip
gave
written
inform
consent
total
elig
adult
patient
prospect
includ
group
octob
march
sampl
patient
evalu
use
among
patient
hospit
complet
clinic
data
remain
patient
lost
outpati
transfer
hospit
control
group
elig
adult
patient
retrospect
enrol
octob
march
figur
baselin
characterist
patient
group
shown
tabl
among
respiratori
sampl
assess
use
posit
neg
detect
pathogen
includ
influenza
viru
n
influenza
b
n
pneumonia
n
adenoviru
n
human
rhinovirusenteroviru
n
coronaviru
n
parainfluenza
viru
n
human
metapneumoviru
n
rsv
n
tabl
support
inform
mix
infect
multipl
pathogen
detect
six
patient
influenza
virusrsv
n
influenza
virushuman
metapneumoviru
n
influenza
n
pneumoniaehuman
rhinovirusenteroviru
n
human
n
adenoviruscoronaviru
n
sampl
result
influenza
anot
subtyp
case
subtyp
perform
use
consequ
influenza
viru
subtyp
detect
sampl
remain
two
sampl
among
patient
group
receiv
antivir
treatment
includ
oseltamivir
acyclovir
compar
control
group
p
adjust
antibiot
therapi
record
patient
group
compar
control
group
p
consequ
find
regard
influenza
patient
isol
neg
pressur
ward
singl
ward
includ
seven
highli
pathogen
case
contrast
control
group
compar
isol
measur
undertaken
compar
antimicrobi
use
intervent
control
group
found
two
group
compar
baselin
characterist
tabl
compar
control
group
intervent
group
show
signific
decreas
antimicrobi
ddd
control
group
vs
intervent
group
p
howev
exclud
antivir
drug
detect
significantli
lower
antibioticantifung
ddd
vs
p
intervent
group
patient
posit
result
antimicrobi
antibioticantifung
ddd
significantli
lower
compar
control
group
antimicrobi
vs
p
antibioticsantifung
vs
p
howev
patient
intervent
group
neg
result
ddd
significantli
differ
control
group
patient
antimicrobi
vs
p
antibioticsantifung
vs
p
tabl
studi
appli
diagnosi
certain
type
pneumonia
caus
mainli
virus
atyp
pathogen
found
detect
pathogen
specimen
higher
detect
rate
obtain
techniqu
appli
gener
pneumonia
result
therefor
show
appli
clinic
would
provid
higher
probabl
identifi
causal
pathogen
microorgan
find
present
studi
also
confirm
sputum
balf
could
use
sampl
test
contrast
manufactur
assert
np
store
viral
transport
media
vtm
suitabl
materi
compat
inde
obtain
posit
result
type
respiratori
tract
specimen
notabl
howev
perform
test
specimen
high
viscos
sputum
essenti
otherwis
reaction
like
fail
sampl
follow
procedur
describ
use
clean
swab
stir
sputum
place
vtm
pathogen
transfer
low
viscos
medium
suitabl
previou
studi
report
lower
respiratori
tract
specimen
accord
higher
sampl
prioriti
ie
balf
sputum
np
indic
perform
patient
pneumonia
could
improv
use
consist
present
studi
obtain
higher
posit
rate
use
balf
sputum
sampl
use
np
although
differ
signific
vs
p
moreov
recent
year
saliva
also
shown
potenti
suitabl
materi
molecular
detect
respiratori
prospect
enrol
patient
diagnos
period
octob
march
attempt
identifi
causal
pathogen
accordingli
found
influenza
viru
commonli
report
causal
agent
follow
influenza
b
viru
adenoviru
rhinovirusenter
viru
etc
studi
adult
viral
pneumonia
report
similar
pattern
pathogen
influenza
virus
predomin
causal
agent
although
proport
influenza
virus
detect
present
studi
notabl
higher
vs
worth
note
commerci
use
present
studi
identif
influenza
viru
limit
subtyp
wherea
subtyp
provid
vagu
result
subtyp
influenza
howev
mainland
china
influenza
viru
one
epidem
strain
associ
inde
strain
particularli
preval
winter
spring
compar
influenza
infect
patient
tend
present
clinic
sever
manifest
requir
aggress
treatment
thu
case
subtyp
necessari
studi
obtain
test
result
influenza
viru
subtyp
case
among
final
identifi
base
pcr
consequ
clinic
practic
report
subtyp
influenza
viru
subtyp
particularli
avian
influenza
viru
includ
carri
immedi
find
present
studi
show
offer
rel
short
turnaround
time
compar
tradit
method
median
turnaround
time
sampl
report
result
physician
hour
compar
cultur
hour
serum
igm
test
hour
featur
may
particular
benefit
respect
clinic
manag
pneumonia
unknown
caus
present
studi
found
patient
group
receiv
antivir
treatment
significantli
higher
control
group
p
among
patient
receiv
posit
test
result
influenza
viru
treat
oseltamivir
notabl
higher
report
studi
carri
unit
moreov
adjust
antibiot
therapi
report
patient
group
compar
control
group
find
strongli
indic
result
test
may
assist
clinic
decis
make
particularli
respect
reduc
unnecessari
antibiot
usag
treatment
rapid
identif
pathogen
caus
respiratori
tract
infect
essenti
clinic
public
health
valu
present
studi
enrol
patient
promptli
isol
soon
diagnosi
influenza
viru
infect
establish
contrast
control
group
patient
receiv
precis
diagnosi
caus
agent
compar
isol
measur
undertaken
lack
accur
diagnosi
may
lead
delay
patient
isol
consequ
wider
spread
virus
moreov
patient
conscious
sought
regularli
analyz
viral
nucleic
acid
patient
respiratori
specimen
use
pcr
patient
discharg
nucleic
acid
test
prove
neg
therebi
reduc
risk
diseas
spread
evalu
clinic
impact
compar
antibiot
use
adult
patient
cohort
histor
control
cohort
latter
diagnos
use
convent
method
found
compar
control
cohort
intervent
group
significantli
lower
antimicrobi
ddd
particularli
respect
use
antibiot
antifung
drug
result
thu
serv
highlight
given
benefit
accur
diagnosi
etiolog
reason
antibiot
usag
could
achiev
result
partial
consist
find
previous
publish
studi
exampl
roger
et
evalu
outcom
pediatr
patient
month
year
old
admit
hospit
acut
respiratori
ill
similar
find
present
studi
found
use
facilit
reduct
durat
antibiot
use
length
hospit
howev
anoth
random
control
trial
discov
use
associ
reduct
overal
durat
antibiot
nevertheless
higher
number
patient
group
receiv
singl
dose
brief
cours
antibiot
control
group
given
inconclus
find
studi
requir
concern
impact
clinic
decis
regard
pneumonia
compar
durat
hospit
stay
two
group
result
intervent
group
unexpectedli
show
longer
durat
hospit
stay
control
group
vs
day
p
one
reason
explan
subject
intervent
group
sever
case
pneumonia
control
group
higher
psi
tabl
sever
condit
may
lead
prolong
hospit
stay
importantli
stricter
criteria
discharg
requir
intervent
group
accord
regul
sanction
chines
ministri
public
health
discharg
influenza
patient
demand
recoveri
condit
two
consecut
neg
test
result
viral
nucleic
acid
respiratori
specimen
therefor
intervent
group
patient
posit
influenza
took
pcr
test
patient
could
discharg
hospit
met
criteria
contrast
control
group
lack
precis
diagnosi
caus
agent
criteria
requir
practic
applic
prolong
length
stay
howev
believ
addit
benefit
concern
public
health
diseas
control
achiev
present
studi
one
sever
examin
applic
compar
publish
studi
studi
focus
adult
sever
pneumonia
condit
best
knowledg
studi
cover
two
consecut
pandem
season
importantli
describ
posit
clinic
impact
particularli
term
antibiot
use
similarli
duan
et
examin
use
manag
lower
respiratori
tract
infect
larger
popul
beij
shorter
length
hospit
reduct
antibiot
use
observ
studi
howev
tend
focu
perform
mere
descript
detect
pathogen
studi
howev
limit
notabl
sampl
size
limit
studi
conduct
singl
locat
may
thu
limit
gener
applic
find
addit
studi
includ
two
cohort
differ
time
period
henc
may
differ
factor
influenc
clinician
behavior
two
period
account
analysi
furthermor
incid
variou
respiratori
virus
may
vari
across
two
period
may
thu
limit
valid
direct
comparison
clinic
outcom
conclus
rapid
sensit
naat
method
use
diagnosi
adult
two
recent
year
shanghai
common
pathogen
caus
identifi
influenza
viru
howev
regard
taken
consider
current
version
unabl
directli
detect
nevertheless
result
obtain
studi
show
may
make
valuabl
contribut
clinic
decis
make
facilit
reason
use
antibiot
